PharmaShots | Incisive News in 3 Shots

Subscribe Now

Active Polyarticular Course Juvenile Idiopathic Arthritis

Pfizer's Xeljanz (tofacitinib) Receives the US FDA's Approval for Active Polyarticular Course Juvenile Idiopathic Arthritis

Pfizer's Xeljanz (tofacitinib) Receives the US FDA's Approval for Active Polyarticular Course Juvenile Idiopathic Arthritis

September 29, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us